Last updated: February 15, 2026
What Is NDC 64980-0256?
National Drug Code (NDC) 64980-0256 corresponds to Eptinezumab (brand name: Vyepti). It is a monoclonal antibody used for preventive treatment of migraine in adults. It received FDA approval in February 2020.
Market Overview
Market Size and Growth Trajectory
Eptinezumab entered a competitive market segment dominated by calcitonin gene-related peptide (CGRP) inhibitors. The primary competitors include:
- Erenumab (Aimovig)
- Fremanezumab (Ajovy)
- Galcanezumab (Emgality)
The global migraine medication market was valued at approximately $6.4 billion in 2022. Expected compound annual growth rate (CAGR) stands near 4.5% through 2030, driven by increased prevalence, better diagnostic awareness, and expanding indications.
Within the United States, annual spending on CGRP migraine preventives approached $2.4 billion in 2022; Eptinezumab accounted for an estimated $100–150 million of this segment.
Sales Performance
Eptinezumab’s sales began modestly in 2020 but gained momentum with formulary placements and insurance coverage. As of 2022, estimated U.S. sales are approximately $75–100 million. Distribution through specialty pharmacies and infusion centers is a key sales driver.
Market Penetration Challenges
- Administration modality: Intravenous infusion every three months limits convenience compared with self-administered subcutaneous options.
- Pricing and reimbursement: List prices are approximately $3,200–$3,600 per infusion. Insurance coverage varies, impacting patient access.
- Competitive landscape: Erenumab, fremanezumab, and galcanezumab offer subcutaneous self-administration, leading to higher market penetration potential.
Price Projection and Pricing Dynamics
Current Pricing
- Wholesale Acquisition Cost (WAC): $3,200–$3,600 per infusion.
- Average Actual Net Price: Estimated at $2,500–$3,000, after discounts and rebates.
- Per year cost: Given quarterly infusions, annual expenditure stands at $10,000–$12,000 per patient.
Short-to-Medium Term Price Trends (Next 3–5 Years)
- Pricing Stability or Slight Reduction: Price reductions of 10–15% are possible due to biosimilar entry or generic competition, though none currently exist.
- Payer Negotiations: Insurers could negotiate discounts, impacting net prices.
- Market Penetration Impact: Increased adoption could lead to volume-driven revenue growth even if unit prices decline.
Long-Term Price Projections (Next 5–10 Years)
- Potential Price Declines: Up to 30–50% if biosimilar entrants or biosimilar-like agents gain approval.
- Value-Based Pricing: Payers and providers may demand outcomes-based arrangements, potentially reducing effective prices.
- Market Entry Blockades: Limited biosimilar competitors in the U.S. due to patent protections and exclusivities.
Patent and Regulatory Landscape
- Patent Status: The primary patent for eptinezumab expired in 2027; subsequent patent applications may extend exclusivity until 2032.
- Biosimilar Development: Patent expiration opens the door for biosimilar entries, likely reducing prices.
Strategic Implications for Stakeholders
- Manufacturers: Focus on formulary negotiations and expanding indications.
- Payers: Negotiating discounts and establishing value-based arrangements will be critical.
- Investors: Monitoring patent protections and biosimilar pipeline developments is key.
Key Takeaways
- The migraine prevention market is growing steadily, with a focus on CGRP inhibitors.
- NDC 64980-0256 (Vyepti) has a niche advantage as an intravenously administered option.
- Current prices are in the $3,200–$3,600 range per infusion, with annual costs around $10,000–$12,000.
- Market penetration is constrained by convenience and competition from subcutaneous offerings.
- Price reductions are likely within the next 3–5 years due to biosimilar development and payer pressure.
FAQs
1. How does the price of Vyepti compare to other CGRP inhibitors?
It is similar or slightly higher per infusion but may be less competitive due to administration route and convenience.
2. When will biosimilars for eptinezumab arrive?
Patent expiration is projected for 2027, with biosimilar development likely to follow shortly thereafter.
3. What factors could influence future prices?
Patent status, biosimilar market entry, reimbursement negotiations, and value-based pricing agreements.
4. What are the main barriers to market expansion?
Infusion administration inconvenience, high costs, and competitive alternatives offering subcutaneous self-injection.
5. What strategic moves should stakeholders consider?
Invest in formulary negotiations, expand indications, monitor biosimilar developments, and develop outcome-based contracts.
References
- IQVIA. (2022). Market Data on Migraine Medications.
- FDA. (2020). Approval Document for Eptinezumab (Vyepti).
- EvaluatePharma. (2022). Global Migraine Market Forecast.
- CMS. (2022). Update on Reimbursement and Pricing for Specialty Drugs.
- Generic Watch. (2023). Biosimilar Entry and Patent Expirations.
